CL2A-SN-38
Based on 7 publication(s) in Google Scholar
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.97%
- CAS No.: 1279680-68-0
- 화학식: C73H97N11O22
- 분자량:1480.61
-
보관:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CL2A-SN-38
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
All Drug-Linker Conjugates for ADC Isoforms
More
Biological Activity
|
Camptothecins |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1279680-68-0
-
Appearance Solid
-
분자량 1480.61
-
화학식 C73H97N11O22
-
Color Light yellow to yellow
-
SMILES
O=C(O[C@](C1=C(CO2)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C1)=O)(CC)C2=O)OCC6=CC=C(NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7N=NC(CNC(C8CCC(CN9C(C=CC9=O)=O)CC8)=O)=C7)=O)=O)=O)C=C6
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
-
NPJ Precis Oncol
Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease. [Abstract]2026 May 21. PMID: 42168339 -
J Med Chem
2025 Jul 20. PMID: 40685636 -
Pharmaceutics
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. [Abstract]2025 Jul 25;17(8):967. PMID: 40870990
CL2A-SN-38 purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2025 Jul 25;17(8):967. [Abstract]
412a ADC with dual MMAF and SN38 payloads improved potency and efficacy over single-payload 412a ADCs. A panel of 8 cell lines consisting of gastric, pancreatic, small cell lung, and triple negative breast cancer cell lines was treated with a molar (M) dilution series of 412a-MMAF, 412a-SN38, or 412a-druxtecan (Dxd), 412a-MMAF+SN38 dual-payload ADC, and unconjugated 412a for 72 h. Cell viability at each concentration of ADC was determined using a luminescent readout of ATP levels in relative light units (RLU). Data were shown from two representative cancer cell lines, BxPC-3 and MKN45 cells. Curves were fitted using a nonlinear regression.
CL2A-SN-38 purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2025 Jul 25;17(8):967. [Abstract]
Half-maximal inhibitory concentration (IC50) values were generated from cell viability curves to determine the potency of each test article. Each data point represented a different cell line. Groups without 8 data points had cell lines that were not responsive enough to the ADC to generate an IC50 value.
-
AAPS J
Selection of Payloads for Antibody-Drug Conjugates Targeting Ubiquitously Expressed Tumor-Associated Antigens: a Case Study. [Abstract]2022 May 27;24(4):70. PMID: 35624189
CL2A-SN-38 purchased from MedChemExpress. Usage Cited in: AAPS J. 2022 May 27;24(4):70. [Abstract]
SY02-SN-38 was the antibody-drug conjugate (ADC) prepared by direct conjugation of the antibody SY02 with CL2A-SN-38. In vitro comparison of cytotoxicity of SY02-ADCs in Trop-2-expressing CFPAC-1 cells and MDA-MB-468 cells was conducted.
CL2A-SN-38 purchased from MedChemExpress. Usage Cited in: AAPS J. 2022 May 27;24(4):70. [Abstract]
SY02-SN-38 was the antibody-drug conjugate (ADC) prepared by direct conjugation of the antibody SY02 with CL2A-SN-38. The in vivo antitumor activity of SY02-ADCs in CFPAC-1 xenograft mouse models was evaluated.
CL2A-SN-38 purchased from MedChemExpress. Usage Cited in: AAPS J. 2022 May 27;24(4):70. [Abstract]
SY02-SN-38 was the antibody-drug conjugate (ADC) prepared by direct conjugation of the antibody SY02 with CL2A-SN-38. Plasma concentration–time curves of total antibody and free payloads were presented.
-
-
용액&용해도
DMSO : 100 mg/mL (67.54 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (1.40 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.08 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (1.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (275 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. [Content Brief]
[2]. Thomas M Cardillo, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17(10):3157-69. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6754 mL | 3.3770 mL | 6.7540 mL | 16.8849 mL |
| 5 mM | 0.1351 mL | 0.6754 mL | 1.3508 mL | 3.3770 mL | |
| 10 mM | 0.0675 mL | 0.3377 mL | 0.6754 mL | 1.6885 mL | |
| 15 mM | 0.0450 mL | 0.2251 mL | 0.4503 mL | 1.1257 mL | |
| 20 mM | 0.0338 mL | 0.1688 mL | 0.3377 mL | 0.8442 mL | |
| 25 mM | 0.0270 mL | 0.1351 mL | 0.2702 mL | 0.6754 mL | |
| 30 mM | 0.0225 mL | 0.1126 mL | 0.2251 mL | 0.5628 mL | |
| 40 mM | 0.0169 mL | 0.0844 mL | 0.1688 mL | 0.4221 mL | |
| 50 mM | 0.0135 mL | 0.0675 mL | 0.1351 mL | 0.3377 mL | |
| 60 mM | 0.0113 mL | 0.0563 mL | 0.1126 mL | 0.2814 mL |
CL2A-SN-38 Related Classifications
HY-128946 Related Classifications
Powered by Bioz